AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2021
Dec 30, 2021
31542_dirs_2021-12-30_27fbcc43-723d-4cdf-b1e3-fc9bb9133c6d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2021-12-28
Reporting Person: Harper Molly (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-28 | Options to purchase common stock | $7.07 | A | 20000 | Acquired | 2028-12-28 | Common Stock (20000) | Direct |
Footnotes
F1: Derivative securities vest in equal tranches, 1/3rd on December 28, 2022, 1/3rd on December 28, 2023 and 1/3rd on December 28, 2024.
More from CATALYST PHARMACEUTICALS, INC.
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6